Consistently, we observed a significant (P < 0.05) reduction in the expression of Ifng and IFN-γ signaling–related genes (e.g., Ifngr1, Cd274, Irf1, Irf9), antigen presentation–related genes (e.g., Tap1, Tap2), and MHC-I (e.g., H2-k1, H2-q4, H2-23) and MHC-II (e.g., H2-t10 and H2-aa) genes in PRC2-loss versus PRC2-wt tumors (Figure 6D), indicating impaired tumor immunogenicity by tumor cell–intrinsic PRC2 inactivation. This evidence concerns the gene IRF9 and neoplasm.